JP2013501802A5 - - Google Patents

Download PDF

Info

Publication number
JP2013501802A5
JP2013501802A5 JP2012524836A JP2012524836A JP2013501802A5 JP 2013501802 A5 JP2013501802 A5 JP 2013501802A5 JP 2012524836 A JP2012524836 A JP 2012524836A JP 2012524836 A JP2012524836 A JP 2012524836A JP 2013501802 A5 JP2013501802 A5 JP 2013501802A5
Authority
JP
Japan
Prior art keywords
metabolic syndrome
peptide
pharmaceutical composition
blood
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012524836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501802A (ja
JP5909182B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/045160 external-priority patent/WO2011019809A1/en
Publication of JP2013501802A publication Critical patent/JP2013501802A/ja
Publication of JP2013501802A5 publication Critical patent/JP2013501802A5/ja
Application granted granted Critical
Publication of JP5909182B2 publication Critical patent/JP5909182B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012524836A 2009-08-12 2010-08-11 代謝性症候群を予防し又は治療するための方法 Active JP5909182B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23327509P 2009-08-12 2009-08-12
US61/233,275 2009-08-12
PCT/US2010/045160 WO2011019809A1 (en) 2009-08-12 2010-08-11 Methods for preventing or treating metabolic syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015250186A Division JP2016041762A (ja) 2009-08-12 2015-12-22 代謝性症候群を予防し又は治療するための方法

Publications (3)

Publication Number Publication Date
JP2013501802A JP2013501802A (ja) 2013-01-17
JP2013501802A5 true JP2013501802A5 (enExample) 2013-10-17
JP5909182B2 JP5909182B2 (ja) 2016-04-26

Family

ID=43586452

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012524836A Active JP5909182B2 (ja) 2009-08-12 2010-08-11 代謝性症候群を予防し又は治療するための方法
JP2015250186A Pending JP2016041762A (ja) 2009-08-12 2015-12-22 代謝性症候群を予防し又は治療するための方法
JP2017039099A Active JP6271785B2 (ja) 2009-08-12 2017-03-02 代謝性症候群を予防し又は治療するための方法
JP2017251017A Pending JP2018052983A (ja) 2009-08-12 2017-12-27 代謝性症候群を予防し又は治療するための方法
JP2019073924A Pending JP2019104768A (ja) 2009-08-12 2019-04-09 代謝性症候群を予防し又は治療するための方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015250186A Pending JP2016041762A (ja) 2009-08-12 2015-12-22 代謝性症候群を予防し又は治療するための方法
JP2017039099A Active JP6271785B2 (ja) 2009-08-12 2017-03-02 代謝性症候群を予防し又は治療するための方法
JP2017251017A Pending JP2018052983A (ja) 2009-08-12 2017-12-27 代謝性症候群を予防し又は治療するための方法
JP2019073924A Pending JP2019104768A (ja) 2009-08-12 2019-04-09 代謝性症候群を予防し又は治療するための方法

Country Status (10)

Country Link
US (4) US20110039766A1 (enExample)
EP (4) EP3427746A1 (enExample)
JP (5) JP5909182B2 (enExample)
CN (3) CN105031605A (enExample)
CA (1) CA2770688C (enExample)
DK (1) DK2464371T3 (enExample)
ES (1) ES2576746T3 (enExample)
HK (1) HK1247820A1 (enExample)
HU (1) HUE029550T2 (enExample)
WO (1) WO2011019809A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3150215A1 (en) 2009-08-24 2017-04-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
CN102711785A (zh) * 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法
EP3100739A1 (en) * 2009-12-31 2016-12-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
EP3170506B1 (en) * 2012-03-30 2018-05-16 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
CN104661670A (zh) * 2012-08-02 2015-05-27 康肽德生物医药技术有限公司 用于治疗动脉粥样硬化的方法
MX2015005102A (es) * 2012-10-22 2016-02-09 Stealth Peptides Int Inc Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo.
WO2014088631A1 (en) * 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
CN117752766A (zh) * 2013-03-01 2024-03-26 康德生物医疗有限公司 治疗线粒体疾病的方法
CN115990242A (zh) 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
EP3049096B1 (en) * 2013-09-27 2018-12-12 Cornell University Use of aromatic-cationic peptides to treat niemann-pick disease characterised by cholesterol-induced mitochondrial dysfunction
EP3077049B1 (en) 2013-12-02 2019-06-19 Stealth BioTherapeutics Corp Compositions for use in treating vitiligo
US10801068B2 (en) 2015-10-16 2020-10-13 The Trustees Of Columbia University In The City Of New York JAG1 expression predicts therapeutic response in NASH
AU2017249218B2 (en) * 2016-04-11 2020-08-27 Arcuate Therapeutics, Inc. Chiral peptides
CN108210914A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪代谢紊乱及其相关病症的药物及其用途
CN110366425A (zh) * 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防动脉粥样硬化及其并发症的方法
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
EP0350221B1 (en) * 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5468798A (en) * 1994-02-18 1995-11-21 Whitford Corporation Basecoat for a coating system
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
CA2329709A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
EP1218544B1 (en) * 1999-10-04 2009-06-03 The University of Medicine and Dentistry of New Jersey TAR RNA binding peptides
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
EP2865385B1 (en) * 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
ZA200509229B (en) * 2003-05-01 2007-03-28 Cornell Res Foundation Inc Method and carrier complexes for delivering molecules to cells
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
US20070110728A1 (en) * 2003-11-28 2007-05-17 Develogen Aktiengesellschaft Method for preventing and treating diabetes using dg119
CA2971928C (en) * 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP1734963A4 (en) * 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
EP3260127B1 (en) * 2005-09-16 2019-05-01 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method of treating cerebral ischemia
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
PL2252312T3 (pl) * 2008-02-07 2014-10-31 Univ Cornell Sposoby zapobiegania lub leczenia insulinooporności
JP5677096B2 (ja) * 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法
CN102711785A (zh) * 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法

Similar Documents

Publication Publication Date Title
JP2013501802A5 (enExample)
JP2018052983A5 (enExample)
JP2007500236A5 (enExample)
JP2012520866A5 (enExample)
JP2013533858A5 (enExample)
JP2015526458A5 (enExample)
JP2010520186A5 (enExample)
JP2010525050A5 (enExample)
CA2513567A1 (en) Cop 1 for treatment of inflammatory bowel diseases
JP2013541583A5 (enExample)
ME02662B (me) Niskofrekventna terapija glatiramer acetatom
JP2012517478A5 (enExample)
CN1379671A (zh) 使用去甲氯雷他定治疗睡眠障碍
JP2011225596A5 (enExample)
WO2012096411A1 (ja) 難治性炎症性腸疾患の予防又は治療方法
JP2013518124A5 (enExample)
JP2002528502A5 (enExample)
CN113164498A (zh) 用于肝病的治疗的组合疗法
JP2012502103A5 (enExample)
IL265761B2 (en) Oral terlipressin compositions for use in treatment of ascites
JP2005508963A5 (enExample)
JP2020500864A5 (enExample)
JP2012525358A5 (enExample)
JP2002544227A5 (enExample)
JP2006514665A5 (enExample)